Post by Yelk on Apr 2, 2020 15:00:39 GMT
Any thoughts on this one? Looks like BionTech taking second quarter. I'm trying to value it. Just love the technical analysis. Highly speculative and seems only catalyst is the acquisition end of second quarter, so any upside is only based off BNTX I believe and what happens over next few months.
Guys heres the deal on March 13 ish BionTech shot up huge on COVID-19 news. This company is under BionTech. The huge jump in one has not reflected on Neon fully yet. The ramp up has been slow and UN-noticed.
Under the terms of the definitive agreement, Neon will, following consummation of the acquisition, merge with Endor Lights, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of BioNTech and become a wholly-owned subsidiary of BioNTech. At closing, BioNTech will issue, and Neon shareholders will receive 0.063 American Depositary Shares (ADS) (each ADS representing one ordinary share of BioNTech) in exchange for each of their shares of Neon. The exchange ratio implies a deal value of $67 million, or $2.18 per share of Neon, based on the closing price of BioNTech’s ADSs of $34.55 on Wednesday, January 15th, 2020.
BNTX is now $55
NTGN- Neon Therapeutics
Current Price $2.53
Sould be $3.50?? 55X0.063. Under the current deal 34.55X0.063 original price. I've been away for a while so all the financial/stock stuff is still grey to me.
BioNTech to acquire Neon (January 16) to strengthen global leadership position in T cell therapies.
while NTGN isn't involed in COVID-19, BioNTech is - COVID-19 vaccine program BNT162 set to enter the clinic in April 2020.
